Advanced
Cell Diagnostics Inc. has launched an in situ RNA detection
technology that it says is more sensitive than protein-based technologies and
more specific than real-time PCR. The company is focusing on clinical
development markets while developing the technology for in vitro diagnostics.
Traditional in situ
detection technologies use antibodies to detect proteins associated with
disease. But in many cases, a protein's expression is too low to be detected.
In some cases, antibodies cannot be developed for the target protein.